The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Artemova M.G.

M.V. Lomonosov Moscow State University, Moscow, Russia

Abdurakhmanov D.T.

Kafedra vnutrennikh, professional'nykh bolezneĭ i pul'monologii Pervogo MGMU im. I.M. Sechenova

Cryoglobulinemic vasculitis in chronic hepatitis C: Genetic aspects

Authors:

Artemova M.G., Abdurakhmanov D.T.

More about the authors

Journal: Therapeutic Archive. 2017;89(4): 110‑114

DOI: 10.17116/terarkh2017894110-114

Read: 1484 times

Download PDF (RU)
Contact the author
Table of contents

CRYOGLOBULINEMIC VASCULITIS IN CHRONIC HEPATITIS C: GENETIC ASPECTS
CRYOGLOBULINEMIC VASCULITIS IN CHRONIC HEPATITIS C: GENETIC ASPECTS

To cite this article:

Artemova MG, Abdurakhmanov DT. Cryoglobulinemic vasculitis in chronic hepatitis C: Genetic aspects. Therapeutic Archive. 2017;89(4):110‑114. (In Russ.)
https://doi.org/10.17116/terarkh2017894110-114

МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Reproductive health of women with hepa­titis C (literature review and own data). Russian Journal of Human Reproduction. 2025;(1):12-20
Viral infe­ctions, quality of game­tes and assi­sted reproductive technologies: a lite­rature review. Russian Journal of Human Reproduction. 2025;(1):44-53
Abstract:

Cryoglobulinemia (CG) is detected in more than 50% of patients with chronic hepatitis C (CHC); however, only 15—25% of them develop cryoglobulinemic vasculitis (CV) that is a systemic vasculitis due to the formation of immune deposits, which affects small (less than medium-sized) vessels and which is frequently fatal for the patient. The causes of CG only in some patients with CHC and the pathogenesis of CV remain unstudied; however, the accumulated data allow one to identify the special contribution of the patient’s genetic factors to the development of the disease. The paper considers the genetic aspects of the development of CG and CV in CHC.

Keywords:

hepatitis C virus
cryoglobulinemia
cryoglobulinemic vasculitis
genetic aspects

Authors:

Artemova M.G.

M.V. Lomonosov Moscow State University, Moscow, Russia

Abdurakhmanov D.T.

Kafedra vnutrennikh, professional'nykh bolezneĭ i pul'monologii Pervogo MGMU im. I.M. Sechenova

Close metadata

References:

  1. Werner CR, Schwarz JM, Egetemeyr DP, Beck R, Malek NP, Lauer UM, Berg CP. Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12. World J Gastroenterol. 2016;22(35):8050-8059. doi:10.3748/wjg.v22.i35.8050
  2. Sise ME, Bloom AK, Wisocky J, Lin MV, Gustafson JL, Lundquist AL, Steele D, Thiim M, Williams WW, Hashemi N, Kim AY, Thadhani R, Chung RT. Treatment of hepatitis C virus-associated mixed cryoglobulinemia with direct-acting antiviral agents. Hepatology. 2016;63(2):408-417. doi:10.1016/j.jhep.2016.09.001
  3. Ignatova TM. Lechenie vnepechenochnykh proyavlenii khronicheskoi HCV-infektsii. Klinicheskaya gepatologiya. 2005;1(2):3-11. (In Russ.)
  4. Gordovskaia NB, Kozlovskaia LV, Milovanova SIu. Cryoglobulinemic vasculitis with renal involvement: A historic aspect of the problem. Terapevticheskii arkhiv. 2015;87(6):112-117. (In Russ.) doi:10.17116/terarkh2015876112-117
  5. Mukhin NA, Kozlovskaya LV, Tegai SV, Gordovskaya NB, Ignatova TM, Kudlinskii IS. HCV-assotsiirovannyi krioglobulinemicheskii vaskulit s tyazhelym porazheniem pochek i razvitiem V-kletochnoi limfomy. Sovremennye vozmozhnosti izmeneniya prognoza s pomoshch'yu monoklonal'nykh antitel k SD20 i protivovirusnoi terapii. Klinicheskaya nefrologiya. 2011;2:61-69. (In Russ.)
  6. Pal'shina SG, Vasil'ev VI. Krioglobulinemicheskii vaskulit. Nauchno-prakticheskaya revmatologiya. 2010;4:59-66. (In Russ.). doi:10.14412/1995-4484-2010-1167
  7. Milovanova SYu, Kozlovskaya LV, Gordovskaya NB. Polymorphism of clinical manifestations of cryoglobulinemia-related vasculitis associated with chronic hepatitis C virus infection. Al'manakh klinicheskoi meditsiny.2014;30:46-51. (In Russ.) doi:10.18786/2072-0505-2014-30-46-51
  8. Vasil'ev VI, Pal'shina SG, Logvinenko OA, Safonova TN, Rodionova EB, Varlamova EYu, Nekrasova TP, Radenska-Lopovok SG, Probatova NA, Aleksandrova EN, Nasonov EL. HCV-associated cryoglobulinemic vasculitis. Terapevticheskii arkhiv. 2012;5:35-42. (In Russ.)
  9. Ignatova TM, Mukhin NA. Current possibilities for treatment for hepatitis C virus-induced cryoglobulinemic vasculitis and B-cell lymphoma. Terapevticheskii arkhiv. 2012;84(11):81-88. (In Russ.)
  10. Allison RD, Tong X, Moorman AC, Ly KN, Rupp L, Xu F, Gordon SC, Holmberg SD. Increased incidence of cancer and cancer-related mortality among persons with chronic hepatitis C infection, 2006-2010. J Hepatol. 2015;63(4):822-828. doi:10.1016/j.jhep.2015.04.021
  11. Zignego AL, Wojcik GL, Cacoub P, Visentini M, Casato M, Mangia A, Latanich R, Charles ED, Gragnani L, Terrier B, Piazzola V, Dustin LB, Khakoo SI, Busch MP, Lauer GM, Kim AY, Alric L, Thomas DL, Duggal P. Genome-wide association study of hepatitis C virus- and cryoglobulin-related vasculitis. Genes Immun. 2014;15(7):500-505. doi:10.1038/gene.2014.41
  12. Sinico RA, Ribero ML, Fornasieri A, Renoldi P, Zhou J, Fasola M, Portera G, Arrigo G, Gibelli A, D'Amico G, et al. Hepatitis C virus genotype in patients with essential mixed cryoglobulinaemia. QJM. 1995;88(11):805-810.
  13. Willems M, Sheng L, Roskams T, Ramdani B, Doutrelepont JM, Nevens F, Durez P, Treille S, Adler M, Desmet V, et al. Hepatitis C virus and its genotypes in patients suffering from chronic hepatitis C with or without a cryoglobulinemia-related syndrome. J Med Virol. 1994;44(3):266-271.
  14. Frangeul L, Musset L, Cresta P, Cacoub P, Huraux JM, Lunel F. Hepatitis C virus genotypes and subtypes in patients with hepatitis C, with and without cryoglobulinemia. J Hepatol. 1996;25(4):427-432.
  15. Gerotto M, Dal Pero F, Loffreda S, Bianchi FB, Alberti A, Lenzi M. A 385 insertion in the hypervariable region 1 of hepatitis C virus E2 envelope protein is found in some patients with mixed cryoglobulinemia type 2. Blood. 2001;98(9):2657-2663.
  16. Bianchettin G, Bonaccini C, Oliva R, Tramontano A, Cividini A, Casato M, Merlini G, Silini E, Mondelli MU. Analysis of hepatitis C virus hypervariable region 1 sequence from cryoglobulinemic patients and associated controls. J Virol. 2007;81(9):4564-4571. doi:10.1128/JVI.02104-06
  17. Rigolet A, Cacoub P, Schnuriger A, Vallat L, Cahour A, Ghillani P, Davi F, Benhamou Y, Piette JC, Thibault V. Genetic heterogeneity of the hypervariable region I of Hepatitis C virus and lymphoproliferative disorders. Leukemia. 2005;19(6):1070-1076. doi:10.1038/sj.leu.2403731
  18. Ferri C, Pietrogrande M, Cecchetti R, Tavoni A, Cefalo A, Buzzetti G, Vitali C, Bombardieri S. Low-antigen-content diet in the treatment of patients with mixed cryoglobulinemia. Am J Med. 1989;87(5):519-524.
  19. Pozzato G, Burrone O, Baba K, Matsumoto M, Hijiiata M, Ota Y, Mazzoran L, Baracetti S, Zorat F, Mishiro S, Efremov DG. Ethnic difference in the prevalence of monoclonal B-cell proliferation in patients affected by hepatitis C virus chronic liver disease. J Hepatol. 1999;30(6):990-994.
  20. Gragnani L, Fognani E, Piluso A, Zignego AL. Hepatitis C virus-related mixed cryoglobulinemia: is genetics to blame? World J Gastroenterol. 2013;19(47):8910-8915. doi:10.3748/wjg.v19.i47.8910
  21. Migliorini P, Bombardieri S, Castellani A, Ferrara GB. HLA antigens in essential mixed cryoglobulinemia. Arthritis Rheum. 1981;24(7):932-936.
  22. Lenzi M, Frisoni M, Mantovani V, Ricci P, Muratori L, Francesconi R, Cuccia M, Ferri S, Bianchi FB. Haplotype HLA-B8-DR3 confers susceptibility to hepatitis C virus-related mixed cryoglobulinemia. Blood. 1998;91(6):2062-2066.
  23. Amoroso A, Berrino M, Canale L, Cornaglia M, Guarrera S, Mazzola G, Savoldi S, Scolari F, Sallberg M, Clementi M, Gabrielli A. Are HLA class II and immunoglobulin constant region genes involved in the pathogenesis of mixed cryoglobulinemia type II after hepatitis C virus infection? J Hepatol. 1998;29(1):36-44.
  24. Cacoub P, Renou C, Kerr G, Hue S, Rosenthal E, Cohen P, Kaplanski G, Charlotte F, Thibault V, Ghillani P, Piette JC, Caillat-Zucman S. Influence of HLA-DR phenotype on the risk of hepatitis C virus-associated mixed cryoglobulinemia. Arthritis Rheum. 2001;44(9):2118-2124. doi:10.1002/1529-0131(200109)44:92118::aid-art3643.0.co;2-x.
  25. Amoroso A, Berrino M, Canale L, Cornaglia M, Guarrera S, Mazzola G, Savoldi S, Scolari F, Sallberg M, Clementi M, Gabrielli A. Are HLA class II and immunoglobulin constant region genes involved in the pathogenesis of mixed cryoglobulinemia type II after hepatitis C virus infection? J Hepatol. 1998;29(1):36-44.
  26. De Re V, Caggiari L, De Vita S, Mazzaro C, Lenzi M, Galli M, Monti G, Ferri C, Zignego AL, Gabrielli A, Sansonno D, Dammacco F, Libra M, Sacchi N, Talamini R, Spina M, Cannizzaro R, Guidoboni M, Dolcetti R. Genetic insights into the disease mechanisms of type II mixed cryoglobulinemia induced by hepatitis C virus. Dig Liver Dis. 2007;39(Suppl.1):S65-71.
  27. Hue S, Cacoub P, Renou C, Halfon P, Thibault V, Charlotte F, Picon M, Rifflet H, Piette JC, Pol S, Caillat-Zucman S. Human leukocyte antigen class II alleles may contribute to the severity of hepatitis C virus-related liver disease. J Infect Dis. 2002;186(1):106-109. doi:10.1086/341086
  28. Minton EJ, Smillie D, Neal KR, Irving WL, Underwood JC, James V. Association between MHC class II alleles and clearance of circulating hepatitis C virus. Members of the Trent Hepatitis C Virus Study Group. J Infect Dis. 1998;178(1):39-44.
  29. Peano G, Menardi G, Ponzetto A, Fenoglio LM. HLA-DR5 antigen. A genetic factor influencing the outcome of hepatitis C virus infection? Arch Intern Med. 1994;154(23):2733-2736.
  30. Lied GA, Berstad A. Functional and clinical aspects of the B-cell-activating factor (BAFF): a narrative review. Scand J Immunol. 2011;73(1):1-7. doi:10.1111/j.1365-3083.2010.02470.x
  31. Tarantino G, Marco VD, Petta S, Almasio PL, Barbaria F, Licata A, Bosco GL, Tripodo C, Stefano RD, Craxi A. Serum BLyS/BAFF predicts the outcome of acute hepatitis C virus infection. J Viral Hepat. 2009;16(6):397-405. doi:10.1111/j.1365-2893.2009.01093.x
  32. Toubi E, Gordon S, Kessel A, Rosner I, Rozenbaum M, Shoenfeld Y, Zuckerman E. Elevated serum B-Lymphocyte activating factor (BAFF) in chronic hepatitis C virus infection: association with autoimmunity. J Autoimmun. 2006;27(2):134-139. doi:10.1016/j.jaut.2006.07.005
  33. Sene D, Limal N, Ghillani-Dalbin P, Saadoun D, Piette JC, Cacoub P. Hepatitis C virus-associated B-cell proliferation--the role of serum B lymphocyte stimulator (BLyS/BAFF). Rheumatology (Oxford). 2007;46(1):65-69. doi:10.1093/rheumatology/kel177
  34. Novak AJ, Grote DM, Ziesmer SC, Kline MP, Manske MK, Slager S, Witzig TE, Shanafelt T, Call TG, Kay NE, Jelinek DF, Cerhan JR, Gross JA, Harder B, Dillon SR, Ansell SM. Elevated serum B-lymphocyte stimulator levels in patients with familial lymphoproliferative disorders. J Clin Oncol. 2006;24(6):983-987. doi:10.1200/JCO.2005.02.7938
  35. Ayad MW, Elbanna AA, Elneily DA, Sakr AS. Association of BAFF -871C/T Promoter Polymorphism with Hepatitis C-Related Mixed Cryoglobulinemia in a Cohort of Egyptian Patients. Mol Diagn Ther. 2015;19(2):99-106. doi:10.1007/s40291-015-0134-7
  36. Gragnani L, Piluso A, Giannini C, Caini P, Fognani E, Monti M, Petrarca A, Ranieri J, Razzolini G, Froio V, Laffi G, Zignego AL. Genetic determinants in hepatitis C virus-associated mixed cryoglobulinemia: role of polymorphic variants of BAFF promoter and Fcgamma receptors. Arthritis Rheum. 2011;63(5):1446-1451. doi:10.1002/art.30274
  37. Giannini C, Gragnani L, Piluso A, Caini P, Petrarca A, Monti M, Laffi G, Zignego AL. Can BAFF promoter polymorphism be a predisposing condition for HCV-related mixed cryoglobulinemia? Blood. 2008;112(10):4353-4354. doi:10.1182/blood-2008-07-170613
  38. Takai T. Roles of Fc receptors in autoimmunity. Nat Rev Immunol. 2002;2(8):580-592. doi:10.1038/nri856
  39. Vassilopoulos D, Younossi ZM, Hadziyannis E, Boparai N, Yen-Lieberman B, Hsi E, Villa-Forte A, Ball E, Kimberly RP, Calabrese LH. Study of host and virological factors of patients with chronic HCV infection and associated laboratory or clinical autoimmune manifestations. Clin Exp Rheumatol. 2003;21(6,Suppl.32):S101-111.
  40. Fornasieri A, Armelloni S, Bernasconi P, Li M, de Septis CP, Sinico RA, D'Amico G. High binding of immunoglobulin M kappa rheumatoid factor from type II cryoglobulins to cellular fibronectin: a mechanism for induction of in situ immune complex glomerulonephritis? Am J Kidney Dis. 1996;27(4):476-483.
  41. Avila JJ, Lympany PA, Pantelidis P, Welsh KI, Black CM, du Bois RM. Fibronectin gene polymorphisms associated with fibrosing alveolitis in systemic sclerosis. Am J Respir Cell Mol Biol. 1999;20(1):106-112. doi:10.1165/ajrcmb.20.1.3232
  42. Yang HY, Su SL, Peng YJ, Wang CC, Lee HS, Salter DM, Lee CH. An intron polymorphism of the fibronectin gene is associated with end-stage knee osteoarthritis in a Han Chinese population: two independent case-control studies. BMC Musculoskelet Disord. 2014;15:173. doi:10.1186/1471-2474-15-173
  43. Fabris M, Quartuccio L, Salvin S, Pozzato G, De Re V, Mazzaro C, Ferri C, Baldini C, De Vita S. Fibronectin gene polymorphisms are associated with the development of B-cell lymphoma in type II mixed cryoglobulinemia. Ann Rheum Dis. 2008;67(1):80-83. doi:10.1136/ard.2006.067637
  44. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura M, Ito K, Yano K, Masaki N, Sugauchi F, Izumi N, Tokunaga K, Mizokami M. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41(10):1105-1109. doi:10.1038/ng.449
  45. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Muller T, Bahlo M, Stewart GJ, Booth DR, George J. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009;41(10):1100-1104. doi:10.1038/ng.447
  46. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461(7262):399-401. doi:10.1038/nature08309
  47. Li M, Liu X, Zhou Y, Su SB. Interferon-lambdas: the modulators of antivirus, antitumor, and immune responses. J Leukoc Biol. 2009;86(1):23-32. doi:10.1189/jlb.1208761
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.